Clinical Trials Logo

Maculopathy, Age-Related clinical trials

View clinical trials related to Maculopathy, Age-Related.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05593913 Completed - Clinical trials for Maculopathy, Age Related

Clinical Evaluation of VeriSee AMD in Screening for Age-Related Macular Degeneration

Start date: January 17, 2022
Phase:
Study type: Observational

An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images. The sensitivity and specificity of VeriSee AMD's automated image analysis for screening AMD will be determined through the comparison with the gold standard, which is the judgment of AMD by the ophthalmologists.

NCT ID: NCT01494805 Completed - Clinical trials for Macular Degeneration

Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

AMD
Start date: December 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD). Patients will be randomized to receive one of two doses of rAAV.sFlt-1 or assigned to the control group.

NCT ID: NCT01024998 Completed - Clinical trials for Macular Degeneration

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Start date: January 11, 2010
Phase: Phase 1
Study type: Interventional

This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).

NCT ID: NCT00417846 Completed - Clinical trials for Choroidal Neovascularization

Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)

Start date: January 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine the sensitivity of the optical coherence tomography (OCT) test in detecting neovascular AMD in eyes at high risk for CNV development. In order to test this hypothesis, we are conducting a multi-center clinical study at four participating clinical centers. A total of 227 participants will be enrolled. Participants will be followed-up for a period of two years, or until CNV develops in the study eye for which treatment is recommended, to determine the occurrence of CNV. The fundamental design principles of the study are simplicity and parsimony.

NCT ID: NCT00211419 Completed - Clinical trials for Maculopathy, Age-Related

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).

NCT ID: NCT00058994 Completed - Clinical trials for Macular Degeneration

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

NCT ID: NCT00051129 Completed - Clinical trials for Macular Degeneration

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).